Vir Biotechnology, Inc. (VIR) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
24/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 5 wins, 7 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseVIR / S&P 13.73% / 15.20% |
WinVIR / S&P 1495.93% / 15.00% |
LoseVIR / S&P -53.75% / 50.40% |
| 2026-Q12/3 |
WinVIR / S&P 48.59% / -4.33% |
WinVIR / S&P 213.96% / 11.30% |
LoseVIR / S&P -26.07% / 27.70% |
| 2025-Q41/3 |
WinVIR / S&P 5.60% / 2.65% |
LoseVIR / S&P -7.61% / 9.00% |
LoseVIR / S&P -17.54% / 13.40% |
| 2025-Q31/3 |
WinVIR / S&P 13.29% / 8.12% |
LoseVIR / S&P -78.55% / 4.61% |
LoseVIR / S&P -7.91% / 13.45% |
| 2025-Q21/3 |
LoseVIR / S&P -22.22% / 10.94% |
LoseVIR / S&P -75.91% / 4.83% |
WinVIR / S&P 11.73% / 10.63% |
| 2025-Q10/3 |
LoseVIR / S&P -11.72% / -4.27% |
LoseVIR / S&P -73.79% / 4.98% |
LoseVIR / S&P 5.24% / 10.57% |
| 2024-Q40/3 |
LoseVIR / S&P -2.00% / 2.41% |
LoseVIR / S&P -13.90% / 5.25% |
LoseVIR / S&P -16.78% / 6.15% |
| 2024-Q30/3 |
LoseVIR / S&P -15.84% / 5.89% |
LoseVIR / S&P -33.82% / 5.89% |
LoseVIR / S&P -12.50% / 6.11% |
| 2024-Q21/3 |
LoseVIR / S&P -12.14% / 4.28% |
LoseVIR / S&P -83.93% / 5.38% |
WinVIR / S&P 82.65% / 5.12% |
| 2024-Q11/3 |
LoseVIR / S&P 0.70% / 10.56% |
LoseVIR / S&P -82.16% / 5.71% |
WinVIR / S&P 267.89% / 5.59% |
| 2023-Q40/3 |
LoseVIR / S&P 7.36% / 11.69% |
LoseVIR / S&P -94.67% / 6.81% |
LoseVIR / S&P -220.16% / 7.78% |
| 2023-Q30/3 |
LoseVIR / S&P -61.80% / -3.27% |
LoseVIR / S&P -95.01% / 7.52% |
LoseVIR / S&P -152.64% / -5.03% |
| 2023-Q20/3 |
LoseVIR / S&P 5.41% / 8.74% |
LoseVIR / S&P -76.72% / 9.50% |
LoseVIR / S&P -124.41% / -8.57% |
| 2023-Q10/3 |
LoseVIR / S&P -8.06% / 7.50% |
LoseVIR / S&P -80.81% / 10.77% |
LoseVIR / S&P -112.02% / -15.69% |
| 2022-Q43/3 |
WinVIR / S&P 31.28% / 7.56% |
WinVIR / S&P 47.51% / 11.88% |
WinVIR / S&P -2.05% / -17.99% |
| 2022-Q31/3 |
LoseVIR / S&P -24.30% / -4.88% |
WinVIR / S&P 736.56% / 13.47% |
LoseVIR / S&P -1056.18% / -1.41% |
| 2022-Q22/3 |
WinVIR / S&P -0.97% / -16.10% |
WinVIR / S&P 1053.87% / 13.71% |
LoseVIR / S&P -437.39% / 11.04% |
| 2022-Q11/3 |
LoseVIR / S&P -38.57% / -4.60% |
WinVIR / S&P 3102.56% / 15.97% |
LoseVIR / S&P -391.64% / 42.23% |
| 2021-Q41/3 |
LoseVIR / S&P -3.79% / 11.03% |
WinVIR / S&P 1334.38% / 15.00% |
LoseVIR / S&P VIR unavailable / 96.40% |
| 2021-Q31/3 |
LoseVIR / S&P -7.95% / 0.58% |
WinVIR / S&P 276.11% / 10.77% |
LoseVIR / S&P VIR unavailable / 69.42% |
| 2021-Q21/3 |
LoseVIR / S&P -7.78% / 8.55% |
WinVIR / S&P 143.32% / 6.58% |
LoseVIR / S&P VIR unavailable / 51.81% |
| 2021-Q12/3 |
WinVIR / S&P 91.45% / 6.17% |
WinVIR / S&P 615.67% / -1.06% |
LoseVIR / S&P VIR unavailable / 7.39% |
| 2020-Q41/3 |
LoseVIR / S&P -21.99% / 12.15% |
WinVIR / S&P 843.86% / -3.72% |
LoseVIR / S&P VIR unavailable / -33.42% |
| 2020-Q31/3 |
LoseVIR / S&P -16.21% / 8.93% |
WinVIR / S&P 638.63% / -2.04% |
LoseVIR / S&P VIR unavailable / -27.10% |
| 2020-Q21/3 |
LoseVIR / S&P 19.55% / 20.54% |
WinVIR / S&P 540.75% / -0.46% |
LoseVIR / S&P VIR unavailable / -27.11% |
| 2020-Q11/3 |
WinVIR / S&P 172.52% / -19.60% |
LoseVIR / S&P VIR unavailable / 3.47% |
LoseVIR / S&P VIR unavailable / -14.75% |
| 2019-Q40/3 |
LoseVIR / S&P VIR unavailable / 9.07% |
LoseVIR / S&P VIR unavailable / 5.36% |
LoseVIR / S&P VIR unavailable / 2.99% |
| 2019-Q30/3 |
LoseVIR / S&P VIR unavailable / 1.70% |
LoseVIR / S&P VIR unavailable / 5.02% |
LoseVIR / S&P VIR unavailable / 0.21% |
| 2019-Q20/3 |
LoseVIR / S&P VIR unavailable / 4.30% |
LoseVIR / S&P VIR unavailable / 6.64% |
LoseVIR / S&P VIR unavailable / 8.65% |
| 2019-Q10/3 |
LoseVIR / S&P VIR unavailable / 13.65% |
LoseVIR / S&P VIR unavailable / 8.12% |
LoseVIR / S&P VIR unavailable / 14.29% |
| 2018-Q40/3 |
LoseVIR / S&P VIR unavailable / -13.52% |
LoseVIR / S&P VIR unavailable / 9.05% |
LoseVIR / S&P VIR unavailable / 18.23% |
| 2018-Q30/3 |
LoseVIR / S&P VIR unavailable / 7.71% |
LoseVIR / S&P VIR unavailable / 10.21% |
LoseVIR / S&P VIR unavailable / 19.06% |
| 2018-Q20/3 |
LoseVIR / S&P VIR unavailable / 3.43% |
LoseVIR / S&P VIR unavailable / 9.03% |
LoseVIR / S&P VIR unavailable / 14.46% |
| 2018-Q10/3 |
LoseVIR / S&P VIR unavailable / -0.76% |
LoseVIR / S&P VIR unavailable / 7.68% |
LoseVIR / S&P VIR unavailable / 12.46% |
| 2017-Q40/3 |
LoseVIR / S&P VIR unavailable / 6.64% |
LoseVIR / S&P VIR unavailable / 7.03% |
LoseVIR / S&P VIR unavailable / 13.82% |
| 2017-Q30/3 |
LoseVIR / S&P VIR unavailable / 4.48% |
LoseVIR / S&P VIR unavailable / 5.68% |
LoseVIR / S&P VIR unavailable / 17.57% |
| 2017-Q20/3 |
LoseVIR / S&P VIR unavailable / 3.09% |
LoseVIR / S&P VIR unavailable / 4.83% |
LoseVIR / S&P VIR unavailable / 17.74% |
| 2017-Q10/3 |
LoseVIR / S&P VIR unavailable / 6.07% |
LoseVIR / S&P VIR unavailable / 3.67% |
LoseVIR / S&P VIR unavailable / 13.32% |
| 2016-Q40/3 |
LoseVIR / S&P VIR unavailable / 3.82% |
LoseVIR / S&P VIR unavailable / 2.09% |
LoseVIR / S&P VIR unavailable / 7.05% |
| 2016-Q30/3 |
LoseVIR / S&P VIR unavailable / 3.85% |
LoseVIR / S&P VIR unavailable / 0.20% |
LoseVIR / S&P VIR unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | VIR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 128.95% | 20.78% |
| Annualized return | 128.95% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | VIR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -76.19% | 83.14% |
| Annualized return | -24.95% | 12.86% |
10Y · 2019-10-11 to 2026-08-27
| Metric | VIR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -19.33% | 319.30% |
| Annualized return | -2.13% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |